Vanda Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Vanda Pharmaceuticals announces its 2026 Annual Meeting agenda, including director elections, executive compensation, and a request to increase equity plan shares.
NASDAQ
Vanda Pharmaceuticals Inc. has issued a proxy supplement to explain its Board's decision to retain director Phaedra Chrousos despite her failure to receive a majority vote at the 2024 Annual Meeting, while also confirming the expiration of a controversial Rights Agreement.
NASDAQ
Vanda Pharmaceuticals Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on company matters.
NASDAQ
Vanda Pharmaceuticals is asking stockholders to approve an amendment to its Amended and Restated 2016 Equity Incentive Plan to increase the share reserve and eliminate its term.
NASDAQ
Vanda Pharmaceuticals encourages stockholders to vote FOR all proposals at the virtual Annual Meeting on May 17, 2024.
NASDAQ
DEFA14A: Vanda Pharmaceuticals Urges Stockholders to Vote on Key Proposals at Upcoming Annual Meeting
Vanda Pharmaceuticals encourages stockholders to vote FOR all four proposals at the virtual Annual Meeting on May 17, 2024.
NASDAQ
Vanda Pharmaceuticals is holding its annual meeting on May 17, 2024, to vote on key proposals including the election of directors, ratification of auditors, executive compensation, and an amendment to the equity incentive plan.